PDCD1 and melanoma: Ipilimumab has also been approved for its use in combination with nivolumab (PD-1 inhibitor) for the treatment of unresectable (advanced) melanoma, RCC, and MSI-h (metastatic microsatellite in-stability high) or dMMR (mismatch repair-deficient) colorectal cancer [14].